Massive Edema Secondary to Nivolumab: A Case Report

Meagan Miller and Einhorn Lawrence

Published on: 2019-02-28

Abstract

Lung cancer remains the leading cause of cancer related deaths in the United States. Despite the advent of new treatments, five-year survival of metastatic lung cancer remains unsatisfactory. Immunotherapies are increasingly becoming integrated as a standard of care not only after disease progression on chemotherapy, but as a first line monotherapy in metastatic disease. One such therapy is a check point inhibitor, Nivolumab, which is an IgG4 monoclonal antibody inhibitor of programmed cell death receptor (PD-1). Presented is a rare case of Nivolumab induced massive edema, which has previously been undocumented.